Ironwood Pharmaceuticals vs Ultragenyx Pharmaceutical
IRWD and RARE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IRWD and RARE compare
Ultragenyx Pharmaceutical is the larger company, worth 2.1 times as much as Ironwood Pharmaceuticals ($1.6B against $801M).
Ironwood Pharmaceuticals grew revenue faster over the last twelve months (26.2% versus 17.5% for Ultragenyx Pharmaceutical).
Ironwood Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 33.4% compared with −81.7% at Ultragenyx Pharmaceutical.
Ironwood Pharmaceuticals scores higher on the StockData Score (12 against 9 for Ultragenyx Pharmaceutical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IRWD | RARE |
|---|---|---|
| Size and price | ||
| Market cap | $801M | $1.6B |
| Share price | $4.85 | $16.70 |
| Change, 1 year | 43.9% | −49.5% |
| Change, 5 years | −56.5% | −78.2% |
| Beta (5Y) | 1.05 | 2.12 |
| Employees | 100 | 1,371 |
| StockData Score | ||
| Total score | 12 (better) | 9 |
| Valuation score | 6 (better) | 1 |
| Growth score | 2 | 2 |
| Performance score | 2 (better) | 1 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 6.3× | – |
| P/S | 2.1× (better) | 2.3× |
| EV/EBITDA | 3.1× | – |
| FCF yield | – | −29.7% |
| Fair value | $12.87 | – |
| Margin of safety | 62.3% | – |
| Growth | ||
| Revenue growth (TTM) | 26.2% (better) | 17.5% |
| Revenue growth, 5Y average | −5.3% | 19.9% (better) |
| EPS growth, 5Y average | −25.6% | – |
| Profitability | ||
| Operating margin | 60.1% (better) | −73.6% |
| Net margin | 33.4% (better) | −81.7% |
| FCF margin | – | −68.2% |
| Financial health | ||
| Interest coverage | 7.2× | – |
| Current ratio | 6.06 (better) | 1.73 |
| Altman Z-score | −1.91 (better) | −5.26 |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 97.2% | 108% |
| Held by insiders | 16.0% | 4.0% |
| Insider net buying, 12 months | −$22.6M | −$3.8M (better) |
| Short interest, % of float | 10.7% | 25.0% |
Go deeper
- IRWD stock overview
- IRWD income statement
- IRWD valuation and score
- RARE stock overview
- RARE income statement
- RARE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.